IL145720A0 - Pharmaceutical compositions containing liposome-encapsulated vinca alkaloids - Google Patents

Pharmaceutical compositions containing liposome-encapsulated vinca alkaloids

Info

Publication number
IL145720A0
IL145720A0 IL14572000A IL14572000A IL145720A0 IL 145720 A0 IL145720 A0 IL 145720A0 IL 14572000 A IL14572000 A IL 14572000A IL 14572000 A IL14572000 A IL 14572000A IL 145720 A0 IL145720 A0 IL 145720A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
compositions containing
vinca alkaloids
containing liposome
mol
Prior art date
Application number
IL14572000A
Other languages
English (en)
Original Assignee
Inex Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inex Pharmaceuticals Corp filed Critical Inex Pharmaceuticals Corp
Publication of IL145720A0 publication Critical patent/IL145720A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL14572000A 1999-04-01 2000-03-31 Pharmaceutical compositions containing liposome-encapsulated vinca alkaloids IL145720A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12744499P 1999-04-01 1999-04-01
US13719499P 1999-06-02 1999-06-02
PCT/US2000/008669 WO2000059473A1 (en) 1999-04-01 2000-03-31 Compositions and methods for treating lymphoma

Publications (1)

Publication Number Publication Date
IL145720A0 true IL145720A0 (en) 2002-07-25

Family

ID=26825635

Family Applications (4)

Application Number Title Priority Date Filing Date
IL14572000A IL145720A0 (en) 1999-04-01 2000-03-31 Pharmaceutical compositions containing liposome-encapsulated vinca alkaloids
IL145720A IL145720A (en) 1999-04-01 2001-09-30 Use of vincristine in a liposome capsule for the preparation of a medicinal product for the treatment of cancer
IL212389A IL212389A (en) 1999-04-01 2011-04-14 Vincristine-containing preparations are injected with liposome for use in the treatment of cancer recurrence
IL212390A IL212390A (en) 1999-04-01 2011-04-14 Vincristine-containing preparations are injected with liposome for use in cancer treatment

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL145720A IL145720A (en) 1999-04-01 2001-09-30 Use of vincristine in a liposome capsule for the preparation of a medicinal product for the treatment of cancer
IL212389A IL212389A (en) 1999-04-01 2011-04-14 Vincristine-containing preparations are injected with liposome for use in the treatment of cancer recurrence
IL212390A IL212390A (en) 1999-04-01 2011-04-14 Vincristine-containing preparations are injected with liposome for use in cancer treatment

Country Status (14)

Country Link
EP (3) EP1169021B1 (xx)
JP (3) JP2002541088A (xx)
AT (1) ATE442839T1 (xx)
AU (1) AU777572B2 (xx)
BR (1) BRPI0009448B8 (xx)
CA (1) CA2366787C (xx)
CY (1) CY1109641T1 (xx)
DE (1) DE60042968D1 (xx)
DK (2) DK1169021T3 (xx)
ES (2) ES2524141T3 (xx)
HK (1) HK1152246A1 (xx)
IL (4) IL145720A0 (xx)
PT (1) PT1169021E (xx)
WO (1) WO2000059473A1 (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
ATE442839T1 (de) * 1999-04-01 2009-10-15 Hana Biosciences Inc Zusammensetzungen und methoden zur behandlung lymphoma
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
ATE440593T1 (de) * 2001-03-27 2009-09-15 Phares Pharm Res Nv Verfahren und zusammensetzung zur solubilisierung einer biologisch wirksamen verbindung mit geringer wasserlíslichkeit
KR100822149B1 (ko) * 2002-05-17 2008-04-15 셀진 코포레이션 암 및 기타 질병의 치료 및 관리를 위해 면역 조절화합물을 이용하는 방법 및 조성물
FR2840203B1 (fr) * 2002-05-31 2004-08-27 Scherer Technologies Inc R P Composition pharmaceutique orale pour capsules molles contenant vinorelbine et methode de traitement
US6890558B2 (en) 2002-05-31 2005-05-10 R.P. Scherer Technologies, Inc. Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
WO2005011698A1 (en) * 2003-07-28 2005-02-10 Inex Pharmaceuticals Corporation Combination comprising a liposome-encapsulated vinca alkaloid and a topoisomerase ii inhibitor and the use thereof for treating neoplasia
RU2394596C2 (ru) * 2004-07-09 2010-07-20 Байер Шеринг Фарма Акциенгезельшафт Комбинированная терапия радиоактивно меченым антителом анти-cd20 при лечении в-клеточной лимфомы
ES2382337T3 (es) * 2004-08-10 2012-06-07 Talon Therapeutics, Inc. Composiciones y procedimientos para tratar la leucemia
PL2194987T3 (pl) 2007-09-10 2017-01-31 Boston Biomedical Inc Nowe inhibitory szlaku białka stat3 oraz inhibitorów nowotworowych komórek macierzystych
CA3146422A1 (en) 2008-03-18 2009-09-24 Genentech, Inc. Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
US20110269699A1 (en) * 2008-10-24 2011-11-03 Mitchell Keegan Cancer therapy
RU2655964C2 (ru) * 2012-11-20 2018-05-30 Спектрум Фармасьютикалз, Инк. Улучшенный способ получения инкапсулированного в липосомы винкристина для терапевтического применения
ES2824074T3 (es) * 2013-01-24 2021-05-11 Memorial Sloan Kettering Cancer Center Método para diagnosticar o tratar tumores mediante el uso de liposomas que contienen esfingomielina
JP6433085B2 (ja) 2013-04-09 2018-12-05 ボストン バイオメディカル， インコーポレイテッド がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
TWI678213B (zh) * 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4885172A (en) 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US5171578A (en) 1985-06-26 1992-12-15 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4952408A (en) * 1988-05-23 1990-08-28 Georgetown University Liposome-encapsulated vinca alkaloids and their use in combatting tumors
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
GB9304745D0 (en) * 1993-03-09 1993-04-28 Oncholab Ab Use of pharmaceutical formulations
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5714163A (en) 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
ATE442839T1 (de) * 1999-04-01 2009-10-15 Hana Biosciences Inc Zusammensetzungen und methoden zur behandlung lymphoma

Also Published As

Publication number Publication date
JP5981214B2 (ja) 2016-08-31
DK2266537T3 (en) 2014-12-15
IL212390A0 (en) 2011-06-30
EP2266537A3 (en) 2012-02-22
DE60042968D1 (de) 2009-10-29
IL145720A (en) 2011-05-31
HK1152246A1 (en) 2012-02-24
BRPI0009448B8 (pt) 2021-05-25
ES2333400T3 (es) 2010-02-22
EP2266537B1 (en) 2014-09-03
CA2366787C (en) 2013-03-12
EP1169021B1 (en) 2009-09-16
JP2015071631A (ja) 2015-04-16
EP1169021A1 (en) 2002-01-09
JP2012158602A (ja) 2012-08-23
BRPI0009448B1 (pt) 2018-09-11
IL212389A (en) 2015-07-30
ES2524141T3 (es) 2014-12-04
DK1169021T3 (da) 2010-01-11
WO2000059473A1 (en) 2000-10-12
CA2366787A1 (en) 2000-10-12
ATE442839T1 (de) 2009-10-15
JP2002541088A (ja) 2002-12-03
IL212390A (en) 2014-08-31
EP1985285A2 (en) 2008-10-29
AU777572B2 (en) 2004-10-21
AU4060600A (en) 2000-10-23
CY1109641T1 (el) 2014-08-13
EP1985285A3 (en) 2009-08-12
BR0009448A (pt) 2002-01-08
IL212389A0 (en) 2011-06-30
EP2266537A2 (en) 2010-12-29
PT1169021E (pt) 2009-11-18

Similar Documents

Publication Publication Date Title
IL145720A0 (en) Pharmaceutical compositions containing liposome-encapsulated vinca alkaloids
AP9701019A0 (en) Phenylamino-substituted tricycle derivatives.
BG103417A (en) Condensed pyrimidine bicyclic derivatives
HK1012268A1 (en) Composition containing cisplatin and topotecan as antitumor agent
TWI224595B (en) New benzazepine derivatives, drugs containing these and use of the same for producing drugs
PL341054A1 (en) Novel suppositiories containing an active compound being unstable in acid environments
LU90856I2 (fr) Uprima - apomorphine hydrochloride et ses d-riv-s pharmaceutiquement acceptables
MX9602683A (es) Compuestos de 6-dimetilaminometil-1-fenil-ciclohexano como substancias farmaceuticamente activas.
WO1999043355A3 (en) Formulations containing oxaliplatin
MX9603570A (es) Metodo y composiciones para incrementar la vida media en suero de agentes farmacologicamente activos.
EP0959874A4 (xx)
PL338181A1 (en) Novel chemical compounds
WO1999063976A3 (en) Liver-selective glucocorticoid antagonist for treating diabetes
GB9522885D0 (en) Improvements in or relating to organic compositions
AU576914B2 (en) 5-cyanopyridine-2-diazohydroxide, basic salts thereof
ES8601200A1 (es) Un procedimiento para preparar compuestos de 3-(2-haloetil)-4-oxopirazolo-(5, 1-d)-1, 2, 3, 5-tetrazin-8-carboxamida
IL114646A0 (en) Method of inhibiting leukotriene biosynthesis
GB9308111D0 (en) Active compound from a stonge
AU578125B2 (en) Pyrazine diazohydroxide compounds
MY133596A (en) Compound and method for the treatment of pain
MX9703839A (es) Soluciones intravenosas de lubeluzol.
MX9802933A (es) Derivados novedosos de amina de 2", 3"-didesoxiglicosidos de epipodofilotoxina, metodo de preparacion de los mismos y uso de los mismos con un farmaco y para tratamientos anticancer.
UA30617A (uk) Спосіб кількісного визначення сечовини в лікарських формах з ліпофільною основою
NZ507349A (en) Spisulosine Compounds having antitumour activity